{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T20:19:02Z","timestamp":1783369142540,"version":"3.54.6"},"reference-count":258,"publisher":"Elsevier","isbn-type":[{"value":"9780443470387","type":"print"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/bs.apha.2026.05.002","type":"book-chapter","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T19:56:59Z","timestamp":1779825419000},"page":"1-64","source":"Crossref","is-referenced-by-count":0,"title":["Fundamentals of engineered T cell therapies: From basic design to bells and whistles"],"prefix":"10.1016","author":[{"given":"Janna C.","family":"Minehart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric W.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praise S.","family":"Oo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay G.","family":"Bhoj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/bs.apha.2026.05.002_bib1","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1089\/hum.2013.209","article-title":"A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer","volume":"25","author":"Abate-Daga","year":"2014","journal-title":"Human Gene Therapy"},{"issue":"10254","key":"10.1016\/bs.apha.2026.05.002_bib2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/bs.apha.2026.05.002_bib3","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nature Biotechnology"},{"issue":"4","key":"10.1016\/bs.apha.2026.05.002_bib4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/gt.2011.104","article-title":"Single-chain V\u03b1V\u03b2 T-cell receptors function without mispairing with endogenous TCR chains","volume":"19","author":"Aggen","year":"2012","journal-title":"Gene Therapy"},{"issue":"6","key":"10.1016\/bs.apha.2026.05.002_bib5","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1182\/blood-2005-06-2399","article-title":"IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients","volume":"107","author":"Ahmadzadeh","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/bs.apha.2026.05.002_bib6","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","article-title":"IL15 Enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype","volume":"7","author":"Alizadeh","year":"2019","journal-title":"Cancer Immunology Research"},{"issue":"625","key":"10.1016\/bs.apha.2026.05.002_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg7565","article-title":"An orthogonal IL-2 and IL-2Rbeta system drives persistence and activation of CAR T cells and clearance of bulky lymphoma","volume":"13","author":"Aspuria","year":"2021","journal-title":"Science Translational Medicine"},{"issue":"10","key":"10.1016\/bs.apha.2026.05.002_bib8","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41375-024-02351-2","article-title":"Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia","volume":"38","author":"Atar","year":"2024","journal-title":"Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U. K"},{"issue":"7","key":"10.1016\/bs.apha.2026.05.002_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-engineered T cell therapy in solid tumors: State of the art and perspectives","volume":"9","author":"Baulu","year":"2023","journal-title":"Science Advances"},{"issue":"2","key":"10.1016\/bs.apha.2026.05.002_bib10","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3390\/biomedicines11020459","article-title":"Development of a TGF\u03b2\u2014IL-2\/15 switch receptor for use in adoptive cell therapy","volume":"11","author":"Beck","year":"2023","journal-title":"Biomedicines"},{"issue":"6036","key":"10.1016\/bs.apha.2026.05.002_bib11","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/317430a0","article-title":"Variability and repertoire size of T-cell receptor V alpha gene segments","volume":"317","author":"Becker","year":"1985","journal-title":"Nature"},{"issue":"10297","key":"10.1016\/bs.apha.2026.05.002_bib12","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/bs.apha.2026.05.002_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1664403","article-title":"Non-signaling but all important: How the linker, hinge, and transmembrane domains in the CAR hold it all together","volume":"16","author":"Bernard","year":"2025","journal-title":"Frontiers in Immunology"},{"issue":"5","key":"10.1016\/bs.apha.2026.05.002_bib14","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nbt962","article-title":"High-affinity binders selected from designed ankyrin repeat protein libraries","volume":"22","author":"Binz","year":"2004","journal-title":"Nature Biotechnology"},{"key":"10.1016\/bs.apha.2026.05.002_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1557405","article-title":"Tandem CAR T-cells targeting CD19 and NKG2DL can overcome CD19 antigen escape in B-ALL","volume":"16","author":"Bols\u00e9e","year":"2025","journal-title":"Frontiers in Immunology"},{"issue":"5319","key":"10.1016\/bs.apha.2026.05.002_bib16","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1126\/science.276.5319.1719","article-title":"HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia","volume":"276","author":"Bonini","year":"1997","journal-title":"Science (New York, N. Y.)"},{"issue":"2","key":"10.1016\/bs.apha.2026.05.002_bib17","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1532759","article-title":"Affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE-A10: strategy for selection of an optimal candidate","volume":"8","author":"Border","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/bs.apha.2026.05.002_bib18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-2121-14-32","article-title":"Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis","volume":"14","author":"Brentnall","year":"2013","journal-title":"BMC Cell Biology"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.002_bib19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ymthe.2017.10.002","article-title":"Optimization of IL13R\u03b12-targeted chimeric Antigen receptor T cells for improved anti-tumor efficacy against glioblastoma","volume":"26","author":"Brown","year":"2018","journal-title":"Molecular Therapy"},{"key":"10.1016\/bs.apha.2026.05.002_bib20","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.coi.2017.02.001","article-title":"Stimulating CD27 to quantitatively and qualitatively shape adaptive immunity to cancer","volume":"45","author":"Bullock","year":"2017","journal-title":"Current Opinion in Immunology"},{"issue":"7","key":"10.1016\/bs.apha.2026.05.002_bib21","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1158\/1535-7163.MCT-21-0552","article-title":"Preclinical efficacy of BCMA-directed CAR T cells incorporating a novel D domain antigen recognition domain","volume":"21","author":"Buonato","year":"2022","journal-title":"Molecular Cancer Therapeutics"},{"issue":"197","key":"10.1016\/bs.apha.2026.05.002_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006034","article-title":"Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells","volume":"5","author":"Cameron","year":"2013","journal-title":"Science Translational Medicine"},{"issue":"7","key":"10.1016\/bs.apha.2026.05.002_bib23","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3390\/cells9071720","article-title":"The quest for the best: How TCR affinity, avidity, and functional avidity affect TCR-engineered T-cell antitumor responses","volume":"9","author":"Campillo-Davo","year":"2020","journal-title":"Cells"},{"key":"10.1016\/bs.apha.2026.05.002_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrep.2022.101324","article-title":"GPC3-targeted CAR-T cells secreting B7H3-targeted BiTE exhibit potent cytotoxicity activity against hepatocellular carcinoma cell in the in vitro assay","volume":"31","author":"Cao","year":"2022","journal-title":"Biochemistry and Biophysics Reports"},{"issue":"11","key":"10.1016\/bs.apha.2026.05.002_bib25","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.002_bib26","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/ijc.32663","article-title":"In vitro elimination of epidermal growth factor receptor-overexpressing cancer cells by CD32A-chimeric receptor T cells in combination with cetuximab or panitumumab","volume":"146","author":"Caratelli","year":"2020","journal-title":"International Journal of Cancer"},{"issue":"5","key":"10.1016\/bs.apha.2026.05.002_bib27","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nature Medicine"},{"issue":"3","key":"10.1016\/bs.apha.2026.05.002_bib28","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nchembio.2565","article-title":"Rewiring T-cell responses to soluble factors with chimeric antigen receptors","volume":"14","author":"Chang","year":"2018","journal-title":"Nature Chemical Biology"},{"issue":"7","key":"10.1016\/bs.apha.2026.05.002_bib29","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00262-020-02838-8","article-title":"CD27 enhances the killing effect of CAR T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors","volume":"70","author":"Chen","year":"2021","journal-title":"Cancer Immunology, Immunotherapy: CII"},{"issue":"5","key":"10.1016\/bs.apha.2026.05.002_bib30","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41422-023-00789-0","article-title":"Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness","volume":"33","author":"Chen","year":"2023","journal-title":"Cell Research"},{"issue":"4","key":"10.1016\/bs.apha.2026.05.002_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24044197","article-title":"4-1BB-Based CAR T cells effectively reverse exhaustion and enhance the anti-tumor immune response through autocrine PD-L1 scFv antibody","volume":"24","author":"Cheng","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"8","key":"10.1016\/bs.apha.2026.05.002_bib32","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"The Journal of Clinical Investigation"},{"issue":"2","key":"10.1016\/bs.apha.2026.05.002_bib33","doi-asserted-by":"crossref","first-page":"685","DOI":"10.4049\/jimmunol.1001775","article-title":"A TCR targeting the HLA-A\u204e0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer","volume":"186","author":"Chinnasamy","year":"2011","journal-title":"Journal of Immunology"},{"issue":"12","key":"10.1016\/bs.apha.2026.05.002_bib34","doi-asserted-by":"crossref","first-page":"7647","DOI":"10.4049\/jimmunol.173.12.7647","article-title":"T Cell activation by antibody-like immunoreceptors: Increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity1","volume":"173","author":"Chmielewski","year":"2004","journal-title":"The Journal of Immunology"},{"issue":"17","key":"10.1016\/bs.apha.2026.05.002_bib35","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","article-title":"IL-12 Release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression","volume":"71","author":"Chmielewski","year":"2011","journal-title":"Cancer Research"},{"issue":"6","key":"10.1016\/bs.apha.2026.05.002_bib36","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal chimeric antigen receptors for multiplexed and logical control of T cell responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell"},{"issue":"591","key":"10.1016\/bs.apha.2026.05.002_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Science Translational Medicine"},{"issue":"14","key":"10.1016\/bs.apha.2026.05.002_bib38","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.002_bib39","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1016\/bs.apha.2026.05.002_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115973","article-title":"CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients","volume":"44","author":"Cook","year":"2025","journal-title":"Cell Reports"},{"issue":"8","key":"10.1016\/bs.apha.2026.05.002_bib41","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1016\/j.ymthe.2024.06.023","article-title":"Preclinical efficacy of a HER2 synNotch\/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification","volume":"32","author":"Cortese","year":"2024","journal-title":"Molecular Therapy"},{"issue":"10","key":"10.1016\/bs.apha.2026.05.002_bib42","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s00262-019-02395-9","article-title":"T cell engineering for adoptive T cell therapy: Safety and receptor avidity","volume":"68","author":"D\u2019Ippolito","year":"2019","journal-title":"Cancer Immunology, Immunotherapy: CII"},{"issue":"16","key":"10.1016\/bs.apha.2026.05.002_bib43","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood.2022016101","article-title":"Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRP\u03b1 checkpoint blocker","volume":"141","author":"Dacek","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1016\/bs.apha.2026.05.002_bib44","doi-asserted-by":"crossref","first-page":"E2068","DOI":"10.1073\/pnas.1716266115","article-title":"Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity","volume":"115","author":"Davenport","year":"2018","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"14","key":"10.1016\/bs.apha.2026.05.002_bib45","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for relapsed or refractory high-risk neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"The New England Journal of Medicine"},{"issue":"6059","key":"10.1016\/bs.apha.2026.05.002_bib46","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/320232a0","article-title":"Transfer of specificity by murine alpha and beta T-cell receptor genes","volume":"320","author":"Dembic","year":"1986","journal-title":"Nature"},{"issue":"11","key":"10.1016\/bs.apha.2026.05.002_bib47","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1038\/s41375-024-02392-7","article-title":"Third-generation anti-CD19 CAR T cells for relapsed\/refractory chronic lymphocytic leukemia: A phase 1\/2 study","volume":"38","author":"Derigs","year":"2024","journal-title":"Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U. K"},{"issue":"18","key":"10.1016\/bs.apha.2026.05.002_bib48","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"10.1016\/bs.apha.2026.05.002_bib49","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ymthe.2017.01.011","article-title":"Inducible caspase-9 selectively modulates the toxicities of CD19-specific chimeric antigen receptor-modified T cells","volume":"25","author":"Diaconu","year":"2017","journal-title":"Molecular Therapy"},{"issue":"16","key":"10.1016\/bs.apha.2026.05.002_bib50","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020104730","article-title":"Rewired signaling network in T cells expressing the chimeric antigen receptor (CAR)","volume":"39","author":"Dong","year":"2020","journal-title":"The EMBO Journal"},{"key":"10.1016\/bs.apha.2026.05.002_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.609421","article-title":"The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory\/recurrent multiple myeloma","volume":"12","author":"Duan","year":"2021","journal-title":"Frontiers in Immunology"},{"issue":"21-22","key":"10.1016\/bs.apha.2026.05.002_bib52","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1089\/hum.2022.068","article-title":"Secretion of 4-1BB ligand crosslinked to PD-1 checkpoint inhibitor potentiates chimeric antigen receptor T cell solid tumor efficacy","volume":"34","author":"Dunn","year":"2023","journal-title":"Human Gene Therapy"},{"issue":"3","key":"10.1016\/bs.apha.2026.05.002_bib53","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.ymthe.2021.11.014","article-title":"Enhancing CAR T function with the engineered secretion of C. perfringens neuraminidase","volume":"30","author":"Durgin","year":"2022","journal-title":"Molecular Therapy"},{"issue":"6295","key":"10.1016\/bs.apha.2026.05.002_bib54","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science (New York, N. Y.)"},{"issue":"24","key":"10.1016\/bs.apha.2026.05.002_bib55","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.1158\/1078-0432.CCR-18-0426","article-title":"A phase I\/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia","volume":"24","author":"Enblad","year":"2018","journal-title":"Clinical Cancer Research: an Official Journal of the American Association for Cancer Research"},{"issue":"2","key":"10.1016\/bs.apha.2026.05.002_bib56","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1016\/bs.apha.2026.05.002_bib57","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41551-025-01450-4","article-title":"Bispecific killer cell engager-secreting CAR-T cells redirect natural killer specificity to enhance antitumour responses","volume":"10","author":"Fan","year":"2026","journal-title":"Nature Biomedical Engineering"},{"issue":"215","key":"10.1016\/bs.apha.2026.05.002_bib58","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Science Translational Medicine"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.002_bib59","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","article-title":"Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency","volume":"25","author":"Feucht","year":"2019","journal-title":"Nature Medicine"},{"issue":"5","key":"10.1016\/bs.apha.2026.05.002_bib60","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nature Medicine"},{"issue":"5","key":"10.1016\/bs.apha.2026.05.002_bib61","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.19.01892","article-title":"Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1016\/bs.apha.2026.05.002_bib62","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1182\/blood.2024024104","article-title":"Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies","volume":"144","author":"Frigault","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/bs.apha.2026.05.002_bib63","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1158\/2326-6066.CIR-14-0186","article-title":"Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells","volume":"3","author":"Frigault","year":"2015","journal-title":"Cancer Immunology Research"},{"issue":"3","key":"10.1016\/bs.apha.2026.05.002_bib64","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1016\/bs.apha.2026.05.002_bib65","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005187","article-title":"GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma","volume":"10","author":"Gargett","year":"2022","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"5","key":"10.1016\/bs.apha.2026.05.002_bib66","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008659","article-title":"Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers","volume":"12","author":"Gargett","year":"2024","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"2","key":"10.1016\/bs.apha.2026.05.002_bib67","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034629","article-title":"Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: A phase I clinical trial protocol (ENABLE)","volume":"10","author":"George","year":"2020","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/bs.apha.2026.05.002_bib68","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nature Medicine"},{"issue":"2","key":"10.1016\/bs.apha.2026.05.002_bib69","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1182\/blood.2023020621","article-title":"CD19\/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL","volume":"143","author":"Ghorashian","year":"2024","journal-title":"Blood"},{"key":"10.1016\/bs.apha.2026.05.002_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1546172","article-title":"Tandem CAR-T cell therapy: recent advances and current challenges","volume":"16","author":"G\u00f3mez-Melero","year":"2025","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.apha.2026.05.002_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105872","article-title":"Tandem CD19\/CD22 CAR T-cells as potential therapy for children and young adults with high-risk r\/r B-ALL","volume":"118","author":"Gonz\u00e1lez-Mart\u00ednez","year":"2025","journal-title":"eBioMedicine"},{"issue":"670","key":"10.1016\/bs.apha.2026.05.002_bib72","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abm1463","article-title":"Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies","volume":"14","author":"Goodman","year":"2022","journal-title":"Science Translational Medicine"},{"issue":"9","key":"10.1016\/bs.apha.2026.05.002_bib73","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1007\/s00262-021-02853-3","article-title":"Enhanced anti-tumor efficacy of IL-7\/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models","volume":"70","author":"Goto","year":"2021","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"2","key":"10.1016\/bs.apha.2026.05.002_bib74","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ymthe.2005.03.022","article-title":"Regulatable gene expression systems for gene therapy applications: Progress and future challenges","volume":"12","author":"Goverdhana","year":"2005","journal-title":"Molecular Therapy"},{"key":"10.1016\/bs.apha.2026.05.002_bib75","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2013.32","article-title":"TanCAR: A novel bispecific chimeric antigen receptor for cancer immunotherapy","volume":"2","author":"Grada","year":"2013","journal-title":"Molecular Therapy - Nucleic Acids"},{"issue":"5","key":"10.1016\/bs.apha.2026.05.002_bib76","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1158\/1535-7163.MCT-19-1109","article-title":"Shaping functional avidity of CAR T cells: Affinity, avidity, and antigen density that regulate response","volume":"20","author":"Greenman","year":"2021","journal-title":"Molecular Cancer Therapeutics"},{"issue":"8","key":"10.1016\/bs.apha.2026.05.002_bib77","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/s41590-020-0719-0","article-title":"Inefficient CAR-proximal signaling blunts antigen sensitivity","volume":"21","author":"Gudipati","year":"2020","journal-title":"Nature Immunology"},{"issue":"7","key":"10.1016\/bs.apha.2026.05.002_bib78","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2013-10-535245","article-title":"ICOS-based chimeric antigen receptors program bipolar TH17\/TH1 cells","volume":"124","author":"Guedan","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.002_bib79","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/bs.apha.2026.05.002_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.755639","article-title":"Inclusion of the inducible caspase 9 suicide gene in CAR construct increases safety of CAR.CD19 T cell therapy in B-cell malignancies","volume":"12","author":"Guercio","year":"2021","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.002_bib81","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-015-0099-4","article-title":"Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors","volume":"3","author":"Hammill","year":"2015","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"3","key":"10.1016\/bs.apha.2026.05.002_bib82","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.4049\/jimmunol.1700236","article-title":"Comparison of T cell activities mediated by human TCRs and CARs that use the same recognition domains","volume":"200","author":"Harris","year":"2018","journal-title":"Journal of Immunology"},{"issue":"8","key":"10.1016\/bs.apha.2026.05.002_bib83","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/s41590-020-0732-3","article-title":"Noncanonical binding of Lck to CD3\u03b5 promotes TCR signaling and CAR function","volume":"21","author":"Hartl","year":"2020","journal-title":"Nature Immunology"},{"issue":"2","key":"10.1016\/bs.apha.2026.05.002_bib84","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/cei.12816","article-title":"Soluble and membrane-bound interleukin (IL)-15 R\u03b1\/IL-15 complexes mediate proliferation of high-avidity central memory CD8+ T cells for adoptive immunotherapy of cancer and infections","volume":"186","author":"Hasan","year":"2016","journal-title":"Clinical and Experimental Immunology"},{"issue":"5955","key":"10.1016\/bs.apha.2026.05.002_bib85","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/308149a0","article-title":"Isolation of cDNA clones encoding T cell-specific membrane-associated proteins","volume":"308","author":"Hedrick","year":"1984","journal-title":"Nature"},{"issue":"5955","key":"10.1016\/bs.apha.2026.05.002_bib86","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/308153a0","article-title":"Sequence relationships between putative T-cell receptor polypeptides and immunoglobulins","volume":"308","author":"Hedrick","year":"1984","journal-title":"Nature"},{"issue":"8","key":"10.1016\/bs.apha.2026.05.002_bib87","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"The Journal of Clinical Investigation"},{"issue":"12","key":"10.1016\/bs.apha.2026.05.002_bib88","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1002\/ijc.25960","article-title":"Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling","volume":"129","author":"Hombach","year":"2011","journal-title":"International Journal of Cancer"},{"issue":"4","key":"10.1016\/bs.apha.2026.05.002_bib89","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/onci.19855","article-title":"OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells","volume":"1","author":"Hombach","year":"2012","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/bs.apha.2026.05.002_bib90","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00262-018-2281-2","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions","volume":"68","author":"Hu","year":"2019","journal-title":"Cancer immunology, immunotherapy: CII"},{"issue":"5","key":"10.1016\/bs.apha.2026.05.002_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2024.101530","article-title":"Selective refueling of CAR T cells using ADA1 and CD26 boosts antitumor immunity","volume":"5","author":"Hu","year":"2024","journal-title":"Cell Reports Medicine"},{"issue":"2","key":"10.1016\/bs.apha.2026.05.002_bib92","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","article-title":"The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity","volume":"3","author":"Hudecek","year":"2015","journal-title":"Cancer Immunology Research"},{"issue":"6","key":"10.1016\/bs.apha.2026.05.002_bib93","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/sj.cgt.7700711","article-title":"Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity","volume":"11","author":"Hwang","year":"2004","journal-title":"Cancer Gene Therapy"},{"issue":"531","key":"10.1016\/bs.apha.2026.05.002_bib94","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aan1088","article-title":"Tuning ITAM multiplicity on T cell receptors can control potency and selectivity to ligand density","volume":"11","author":"James","year":"2018","journal-title":"Science Signaling"},{"issue":"575","key":"10.1016\/bs.apha.2026.05.002_bib95","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb6295","article-title":"Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide","volume":"13","author":"Jan","year":"2021","journal-title":"Science Translational Medicine"},{"issue":"9","key":"10.1016\/bs.apha.2026.05.002_bib96","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.bbmt.2010.03.014","article-title":"Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20\/CD19-specific chimeric antigen receptor redirected T cells in humans","volume":"16","author":"Jensen","year":"2010","journal-title":"Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.002_bib97","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","article-title":"CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors","volume":"10","author":"Jin","year":"2019","journal-title":"Nature Communications"},{"issue":"2","key":"10.1016\/bs.apha.2026.05.002_bib98","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/intimm\/dxad033","article-title":"Cytokine signaling in chimeric antigen receptor T-cell therapy","volume":"36","author":"Kagoya","year":"2024","journal-title":"International Immunology"},{"issue":"3","key":"10.1016\/bs.apha.2026.05.002_bib99","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nature Medicine"},{"issue":"7918","key":"10.1016\/bs.apha.2026.05.002_bib100","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41586-022-04801-2","article-title":"Potentiating adoptive cell therapy using synthetic IL-9 receptors","volume":"607","author":"Kalbasi","year":"2022","journal-title":"Nature"},{"issue":"3","key":"10.1016\/bs.apha.2026.05.002_bib101","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/85286","article-title":"Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMHC complex","volume":"2","author":"Kalergis","year":"2001","journal-title":"Nature Immunology"},{"issue":"19","key":"10.1016\/bs.apha.2026.05.002_bib102","doi-asserted-by":"crossref","first-page":"5890","DOI":"10.1158\/1078-0432.CCR-18-3927","article-title":"Bispecific antibodies enable synthetic agonistic receptor-transduced T cells for tumor immunotherapy","volume":"25","author":"Karches","year":"2019","journal-title":"Clinical Cancer Research: an Official Journal of the American Association for Cancer Research"},{"issue":"2","key":"10.1016\/bs.apha.2026.05.002_bib103","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/bs.apha.2026.05.002_bib104","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Molecular Therapy"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.002_bib105","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nature Biotechnology"},{"issue":"7","key":"10.1016\/bs.apha.2026.05.002_bib106","first-page":"689","article-title":"Construction and Pre-clinical evaluation of an Anti-CD19 chimeric antigen receptor","volume":"32","author":"Kochenderfer","year":"2009","journal-title":"Journal of Immunotherapy (Hagerstown, Md.: 1997)"},{"issue":"19","key":"10.1016\/bs.apha.2026.05.002_bib107","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/blood-2010-01-265041","article-title":"Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.apha.2026.05.002_bib108","doi-asserted-by":"crossref","DOI":"10.4161\/2162402X.2014.994446","article-title":"IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo","volume":"4","author":"Koneru","year":"2015","journal-title":"Oncoimmunology"},{"issue":"6168","key":"10.1016\/bs.apha.2026.05.002_bib109","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science (New York, N. Y.)"},{"issue":"6","key":"10.1016\/bs.apha.2026.05.002_bib110","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2006-05-023069","article-title":"Facilitating matched pairing and expression of TCR chains introduced into human T cells","volume":"109","author":"Kuball","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.apha.2026.05.002_bib111","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/0006-291X(87)90502-X","article-title":"Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions","volume":"149","author":"Kuwana","year":"1987","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"10","key":"10.1016\/bs.apha.2026.05.002_bib112","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.cell.2022.03.041","article-title":"Enhanced safety and efficacy of protease-regulated CAR-T cell receptors","volume":"185","author":"Labanieh","year":"2022","journal-title":"Cell"},{"issue":"3","key":"10.1016\/bs.apha.2026.05.002_bib113","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/leu.2017.249","article-title":"Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells","volume":"32","author":"Lai","year":"2018","journal-title":"Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U. K"},{"key":"10.1016\/bs.apha.2026.05.002_bib114","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.omto.2023.07.001","article-title":"Development of a bicistronic anti-CD19\/CD20 CAR construct including abrogation of unexpected nucleic acid sequence deletions","volume":"30","author":"Lam","year":"2023","journal-title":"Molecular Therapy - Oncolytics"},{"issue":"4","key":"10.1016\/bs.apha.2026.05.002_bib115","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/mt.2013.17","article-title":"Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: Clinical evaluation and management of on-target toxicity","volume":"21","author":"Lamers","year":"2013","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"issue":"13","key":"10.1016\/bs.apha.2026.05.002_bib116","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","article-title":"Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience","volume":"24","author":"Lamers","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1016\/bs.apha.2026.05.002_bib117","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2017-05-781351","article-title":"An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma","volume":"131","author":"Lee","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/bs.apha.2026.05.002_bib118","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006699","article-title":"Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy","volume":"11","author":"Lee","year":"2023","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"3","key":"10.1016\/bs.apha.2026.05.002_bib119","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2017-05-787598","article-title":"CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells","volume":"131","author":"Legut","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/bs.apha.2026.05.002_bib120","doi-asserted-by":"crossref","first-page":"12722","DOI":"10.1182\/blood-2022-156635","article-title":"Safety and feasibility of anti-CD19 CAR-T expressing IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma","volume":"140","author":"Lei","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/bs.apha.2026.05.002_bib121","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1182\/bloodadvances.2022008559","article-title":"Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function","volume":"7","author":"Leung","year":"2023","journal-title":"Blood Advances"},{"key":"10.1016\/bs.apha.2026.05.002_bib122","article-title":"Development of Nectin4\/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors","volume":"13","author":"Li","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"18","key":"10.1016\/bs.apha.2026.05.002_bib123","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121322","article-title":"4-1BB enhancement of CAR T function requires NF-\u03baB and TRAFs","volume":"3","author":"Li","year":"2018","journal-title":"JCI insight"},{"issue":"10","key":"10.1016\/bs.apha.2026.05.002_bib124","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1016\/j.ymthe.2024.07.020","article-title":"Armored bicistronic CAR T cells with dominant-negative TGF-\u03b2 receptor II to overcome resistance in glioblastoma","volume":"32","author":"Li","year":"2024","journal-title":"Molecular Therapy"},{"issue":"23","key":"10.1016\/bs.apha.2026.05.002_bib125","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1200\/JCO.23.02019","article-title":"Phase I trial of GD2.CART cells augmented with constitutive interleukin-7 receptor for treatment of high-grade pediatric CNS tumors","volume":"42","author":"Lin","year":"2024","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.002_bib126","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41408-024-01082-y","article-title":"Anti-CD5 CAR-T cells with a tEGFR safety switch exhibit potent toxicity control","volume":"14","author":"Lin","year":"2024","journal-title":"Blood Cancer Journal"},{"issue":"21","key":"10.1016\/bs.apha.2026.05.002_bib127","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz3223","article-title":"Chimeric antigen receptor signaling: Functional consequences and design implications","volume":"6","author":"Lindner","year":"2020","journal-title":"Science Advances"},{"issue":"6","key":"10.1016\/bs.apha.2026.05.002_bib128","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"issue":"17","key":"10.1016\/bs.apha.2026.05.002_bib129","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-15-0159","article-title":"Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Research"},{"issue":"6","key":"10.1016\/bs.apha.2026.05.002_bib130","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","article-title":"A chimeric switch-receptor targeting PD1 augments the efficacy of second generation CAR T-cells in advanced solid tumors","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Research"},{"issue":"7","key":"10.1016\/bs.apha.2026.05.002_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101085","article-title":"A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory\/relapsed B cell lymphoma","volume":"14","author":"Liu","year":"2021","journal-title":"Translational Oncology"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.002_bib132","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1038\/s41598-017-02460-2","article-title":"Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector","volume":"7","author":"Liu","year":"2017","journal-title":"Scientific Reports"},{"issue":"6","key":"10.1016\/bs.apha.2026.05.002_bib133","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nature Medicine"},{"issue":"6","key":"10.1016\/bs.apha.2026.05.002_bib134","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nature Medicine"},{"issue":"3","key":"10.1016\/bs.apha.2026.05.002_bib135","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/bloodadvances.2024012992","article-title":"A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma","volume":"9","author":"Looka","year":"2025","journal-title":"Blood Advances"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.002_bib136","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13046-020-01572-4","article-title":"Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers","volume":"39","author":"Loureiro","year":"2020","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"issue":"6168","key":"10.1016\/bs.apha.2026.05.002_bib137","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science (New York, N. Y.)"},{"issue":"20","key":"10.1016\/bs.apha.2026.05.002_bib138","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-20-0777","article-title":"Coexpression of IL7 and CCL21 increases efficacy of CAR-T cells in solid tumors without requiring preconditioned lymphodepletion","volume":"26","author":"Luo","year":"2020","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.apha.2026.05.002_bib139","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.omto.2022.12.003","article-title":"Disruption of CISH promotes the antitumor activity of human T cells and decreases PD-1 expression levels","volume":"28","author":"Lv","year":"2022","journal-title":"Molecular Therapy Oncolytics"},{"issue":"6","key":"10.1016\/bs.apha.2026.05.002_bib140","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/leu.2016.35","article-title":"High-affinity FR\u03b2-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity","volume":"30","author":"Lynn","year":"2016","journal-title":"Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U. K"},{"issue":"9","key":"10.1016\/bs.apha.2026.05.002_bib141","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nature Medicine"},{"issue":"11","key":"10.1016\/bs.apha.2026.05.002_bib142","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/s41591-020-1039-5","article-title":"Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo","volume":"26","author":"Maldini","year":"2020","journal-title":"Nature Medicine"},{"issue":"11","key":"10.1016\/bs.apha.2026.05.002_bib143","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/s41591-020-1039-5","article-title":"Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo","volume":"26","author":"Maldini","year":"2020","journal-title":"Nature Medicine"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.002_bib144","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1158\/2326-6066.CIR-17-0126","article-title":"Reversible transgene expression reduces fratricide and permits 4-1BB costimulation of CAR T cells directed to T-cell malignancies","volume":"6","author":"Mamonkin","year":"2018","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/bs.apha.2026.05.002_bib145","doi-asserted-by":"crossref","unstructured":"Mansoori, S., Shokrgozar, M. A., Gholizadeh, M., Abdoli, S., Ajdary, S., & Sharifzadeh, Z.\u00a0(2025). A newly developed TGF-\u0392-responsive CAR T cell for enhanced proliferation and cytokine secretion. Advanced Pharmaceutical Bulletin, 15(3), 646\u2013656. https:\/\/doi.org\/10.34172\/apb.025.45483.","DOI":"10.34172\/apb.025.45483"},{"issue":"22","key":"10.1016\/bs.apha.2026.05.002_bib146","doi-asserted-by":"crossref","first-page":"9089","DOI":"10.1073\/pnas.1018771108","article-title":"T-cell triggering thresholds are modulated by the number of antigen within individual T-cell receptor clusters","volume":"108","author":"Manz","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"17","key":"10.1016\/bs.apha.2026.05.002_bib147","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1182\/blood-2009-09-241398","article-title":"IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell\u2013mediated rejection of systemic lymphoma in immunodeficient mice","volume":"115","author":"Markley","year":"2010","journal-title":"Blood"},{"key":"10.1016\/bs.apha.2026.05.002_bib148","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1460266","article-title":"Targeting TGF\u03b2 with chimeric switch receptor and secreted trap to improve T cells anti-tumor activity","volume":"15","author":"Matikhina","year":"2024","journal-title":"Frontiers in Immunology"},{"issue":"16","key":"10.1016\/bs.apha.2026.05.002_bib149","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/bs.apha.2026.05.002_bib150","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.002_bib151","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2602989","article-title":"Fine-tuning affinity and spacer design enhances T cell potency in DLL3 and BCMA CAR T cells","volume":"18","author":"Mazzanti","year":"2025","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.002_bib152","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1038\/s41467-025-60394-0","article-title":"A phase I\/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: Skewing towards NK-like phenotype impairs T cell function and persistence","volume":"16","author":"Mazziotta","year":"2025","journal-title":"Nature Communications"},{"issue":"11","key":"10.1016\/bs.apha.2026.05.002_bib153","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.1073\/pnas.92.11.5042","article-title":"Kinetic proofreading in T-cell receptor signal transduction","volume":"92","author":"McKeithan","year":"1995","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"7","key":"10.1016\/bs.apha.2026.05.002_bib154","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U. K"},{"issue":"4","key":"10.1016\/bs.apha.2026.05.002_bib155","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1053\/j.gastro.2009.10.057","article-title":"Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer","volume":"138","author":"Mlecnik","year":"2010","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.002_bib156","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/s42003-021-02610-3","article-title":"NetTCR-2.0 enables accurate prediction of TCR-peptide binding by using paired TCR\u03b1 and \u03b2 sequence data","volume":"4","author":"Montemurro","year":"2021","journal-title":"Communications Biology"},{"issue":"10","key":"10.1016\/bs.apha.2026.05.002_bib157","first-page":"5276","article-title":"Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy","volume":"46","author":"Moolten","year":"1986","journal-title":"Cancer Research"},{"issue":"14","key":"10.1016\/bs.apha.2026.05.002_bib158","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","article-title":"Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor","volume":"17","author":"Moon","year":"2011","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10.1016\/bs.apha.2026.05.002_bib159","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"Journal of Immunotherapy"},{"issue":"4","key":"10.1016\/bs.apha.2026.05.002_bib160","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Molecular Therapy"},{"issue":"12","key":"10.1016\/bs.apha.2026.05.002_bib161","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2021.100457","article-title":"Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors","volume":"2","author":"Muliaditan","year":"2021","journal-title":"Cell Reports Medicine"},{"key":"10.1016\/bs.apha.2026.05.002_bib162","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: Natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annual Review of Biochemistry"},{"issue":"5","key":"10.1016\/bs.apha.2026.05.002_bib163","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41589-018-0021-8","article-title":"The dTAG system for immediate and target-specific protein degradation","volume":"14","author":"Nabet","year":"2018","journal-title":"Nature Chemical Biology"},{"issue":"4","key":"10.1016\/bs.apha.2026.05.002_bib164","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: A phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nature Medicine"},{"issue":"26","key":"10.1016\/bs.apha.2026.05.002_bib165","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.002_bib166","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/s42003-025-08906-y","article-title":"CD28-mediated linear and parallel costimulatory signaling cooperatively regulate CAR-T cell functions via CAR-CD28 microclusters","volume":"8","author":"Nishikawa","year":"2025","journal-title":"Communications Biology"},{"issue":"6","key":"10.1016\/bs.apha.2026.05.002_bib167","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/s41375-023-01905-0","article-title":"Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML","volume":"37","author":"Nixdorf","year":"2023","journal-title":"Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U. K"},{"issue":"16","key":"10.1016\/bs.apha.2026.05.002_bib168","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168706","article-title":"TGF-\u03b2\/IL-7 chimeric switch receptor-expressing CAR-T cells inhibit recurrence of CD19-positive B cell lymphoma","volume":"22","author":"Noh","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.002_bib169","doi-asserted-by":"crossref","first-page":"5599","DOI":"10.1038\/s41467-025-60816-z","article-title":"Human cancer-targeted immunity via transgenic hematopoietic stem cell progeny","volume":"16","author":"Nowicki","year":"2025","journal-title":"Nature Communications"},{"key":"10.1016\/bs.apha.2026.05.002_bib170","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ygyno.2020.06.089","article-title":"A phase I clinical trial of autologous chimeric antigen receptor (CAR) T cells genetically engineered to secrete IL-12 and to target the MUC16ecto antigen in patients (pts) with MUC16ecto+ recurrent high-grade serous ovarian cancer (HGSOC)","volume":"159","author":"O\u2019Cearbhaill","year":"2020","journal-title":"Gynecologic Oncology"},{"issue":"9","key":"10.1016\/bs.apha.2026.05.002_bib171","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41587-022-01637-z","article-title":"Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells","volume":"41","author":"Oh","year":"2023","journal-title":"Nature Biotechnology"},{"issue":"10","key":"10.1016\/bs.apha.2026.05.002_bib172","first-page":"2215","article-title":"Cellular resistance mechanisms to targeted protein degradation converge toward impairment of the engaged ubiquitin transfer pathway","volume":"14","author":"Ottis","year":"2019","journal-title":"ACS Chemical Biology"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.002_bib173","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"Journal of Hematology & Oncology"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.002_bib174","article-title":"Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity","volume":"7","author":"Park","year":"2017","journal-title":"Scientific Reports"},{"issue":"3","key":"10.1016\/bs.apha.2026.05.002_bib175","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/mt.2010.272","article-title":"T Cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis","volume":"19","author":"Parkhurst","year":"2011","journal-title":"Molecular Therapy"},{"issue":"625","key":"10.1016\/bs.apha.2026.05.002_bib176","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aay8248","article-title":"4-1BB costimulation promotes CAR T cell survival through noncanonical NF-\u03baB signaling","volume":"13","author":"Philipson","year":"2020","journal-title":"Science Signaling"},{"issue":"2","key":"10.1016\/bs.apha.2026.05.002_bib177","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.pan.2019.01.015","article-title":"Plasma IFN-\u03b3-inducible chemokines CXCL9 and CXCL10 correlate with survival and chemotherapeutic efficacy in advanced pancreatic ductal adenocarcinoma","volume":"19","author":"Qian","year":"2019","journal-title":"Pancreatology"},{"issue":"7","key":"10.1016\/bs.apha.2026.05.002_bib178","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.ymthe.2019.04.010","article-title":"Chimeric antigen receptors incorporating D domains targeting CD123 direct potent mono- and Bi-specific antitumor activity of T cells","volume":"27","author":"Qin","year":"2019","journal-title":"Molecular Therapy"},{"key":"10.1016\/bs.apha.2026.05.002_bib179","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","article-title":"Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22","volume":"11","author":"Qin","year":"2018","journal-title":"Molecular Therapy Oncolytics"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.002_bib180","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1038\/s41467-022-33793-w","article-title":"Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis","volume":"13","author":"Qin","year":"2022","journal-title":"Nature Communications"},{"issue":"9","key":"10.1016\/bs.apha.2026.05.002_bib181","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nature Biotechnology"},{"issue":"568","key":"10.1016\/bs.apha.2026.05.002_bib182","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aap9777","article-title":"An immunoproteomic approach to characterize the CAR interactome and signalosome","volume":"12","author":"Ramello","year":"2019","journal-title":"Science Signaling"},{"issue":"12","key":"10.1016\/bs.apha.2026.05.002_bib183","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"Vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin\u2019s lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Molecular Therapy"},{"issue":"8","key":"10.1016\/bs.apha.2026.05.002_bib184","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1\u2013specific TCR\u2013engineered T cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nature Medicine"},{"issue":"Supplement 1","key":"10.1016\/bs.apha.2026.05.002_bib185","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1182\/blood-2024-201799","article-title":"Phase 1 trial of CD30-directed, CCR4 co-expressing chimeric antigen receptor T-cells in patients with CD30+ cutaneous T-cell lymphomas refractory to brentuximab vedotin","volume":"144","author":"Reef","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.002_bib186","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/2326-6066.CIR-17-0211","article-title":"High-affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model","volume":"6","author":"Richman","year":"2018","journal-title":"Cancer Immunology Research"},{"issue":"11","key":"10.1016\/bs.apha.2026.05.002_bib187","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-07-4740","article-title":"A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer","volume":"14","author":"Robertson","year":"2008","journal-title":"Clinical Cancer Research"},{"issue":"30","key":"10.1016\/bs.apha.2026.05.002_bib188","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1200\/JCO.21.00917","article-title":"Durable responses and low toxicity after fast off-rate CD19 chimeric antigen receptor-T therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia","volume":"39","author":"Roddie","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1016\/bs.apha.2026.05.002_bib189","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: The first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"The Journal of Immunology"},{"issue":"25","key":"10.1016\/bs.apha.2026.05.002_bib190","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma","volume":"319","author":"Rosenberg","year":"1988","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1016\/bs.apha.2026.05.002_bib191","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T cells with customized therapeutic response programs using synthetic notch receptors","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"10.1016\/bs.apha.2026.05.002_bib192","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1038\/s41467-023-37863-5","article-title":"Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting","volume":"14","author":"Ruffo","year":"2023","journal-title":"Nature Communications"},{"issue":"5971","key":"10.1016\/bs.apha.2026.05.002_bib193","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/309757a0","article-title":"Complete primary structure of a heterodimeric T-cell receptor deduced from cDNA sequences","volume":"309","author":"Saito","year":"1984","journal-title":"Nature"},{"issue":"544","key":"10.1016\/bs.apha.2026.05.002_bib194","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aat6753","article-title":"Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function","volume":"11","author":"Salter","year":"2018","journal-title":"Science Signaling"},{"issue":"697","key":"10.1016\/bs.apha.2026.05.002_bib195","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abe2606","article-title":"Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function","volume":"14","author":"Salter","year":"2021","journal-title":"Science Signaling"},{"issue":"5","key":"10.1016\/bs.apha.2026.05.002_bib196","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1074-7613(00)80561-0","article-title":"Allelic inclusion of T cell receptor \u03b1 genes poses an autoimmune hazard due to low-level expression of autospecific receptors","volume":"8","author":"Sarukhan","year":"1998","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/bs.apha.2026.05.002_bib197","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"The Journal of Clinical Investigation"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.002_bib198","doi-asserted-by":"crossref","DOI":"10.1093\/noajnl\/vdac185","article-title":"Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13R\u03b12 are effective against heterogeneous glioblastoma","volume":"5","author":"Schmidts","year":"2023","journal-title":"Neuro-Oncology Advances"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.002_bib199","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"The New England Journal of Medicine"},{"issue":"26","key":"10.1016\/bs.apha.2026.05.002_bib200","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.002_bib201","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.2003532","article-title":"Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting","volume":"10","author":"Seitz","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/bs.apha.2026.05.002_bib202","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1038\/s41467-019-12902-2","article-title":"Increased yields and biological potency of knob-into-hole-based soluble MHC class II molecules","volume":"10","author":"Serra","year":"2019","journal-title":"Nature Communications"},{"issue":"11","key":"10.1016\/bs.apha.2026.05.002_bib203","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ajh.25951","article-title":"Commercial anti-CD19 CAR T cell therapy for patients with relapsed\/refractory aggressive B cell lymphoma in a European center","volume":"95","author":"Sesques","year":"2020","journal-title":"American Journal of Hematology"},{"key":"10.1016\/bs.apha.2026.05.002_bib204","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.835762","article-title":"Cancer therapy with TCR-engineered T cells: Current strategies, challenges, and prospects","volume":"13","author":"Shafer","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.002_bib205","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41392-025-02522-2","article-title":"CXCR4-modification enhances CAR-T efficacy by improving tumor tracking and bone marrow homing in B-cell malignancies","volume":"11","author":"Shu","year":"2026","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"11","key":"10.1016\/bs.apha.2026.05.002_bib206","doi-asserted-by":"crossref","first-page":"5556","DOI":"10.1016\/j.ymthe.2025.08.002","article-title":"Optimal pairing of binder and co-stimulatory domains improves dual CART cell efficacy","volume":"33","author":"Shukla","year":"2025","journal-title":"Molecular Therapy"},{"issue":"11","key":"10.1016\/bs.apha.2026.05.002_bib207","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1158\/2159-8290.CD-17-0538","article-title":"Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells","volume":"7","author":"Shum","year":"2017","journal-title":"Cancer Discovery"},{"issue":"9","key":"10.1016\/bs.apha.2026.05.002_bib208","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1089\/hum.2017.021","article-title":"Designed ankyrin repeat proteins as Her2 targeting domains in chimeric antigen receptor-engineered T cells","volume":"28","author":"Siegler","year":"2017","journal-title":"Human Gene Therapy"},{"issue":"10","key":"10.1016\/bs.apha.2026.05.002_bib209","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1016\/j.ymthe.2024.09.015","article-title":"Approval of the first TCR-based cell therapy","volume":"32","author":"Singh","year":"2024","journal-title":"Molecular Therapy"},{"issue":"10","key":"10.1016\/bs.apha.2026.05.002_bib210","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1073\/pnas.0600205103","article-title":"Signals from OX40 regulate nuclear factor of activated T cells c1 and T cell helper 2 lineage commitment","volume":"103","author":"So","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6379","key":"10.1016\/bs.apha.2026.05.002_bib211","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1126\/science.aar3246","article-title":"Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes","volume":"359","author":"Sockolosky","year":"2018","journal-title":"Science (New York, N. Y.)"},{"issue":"3","key":"10.1016\/bs.apha.2026.05.002_bib212","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/blood-2011-03-344275","article-title":"CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo","volume":"119","author":"Song","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/bs.apha.2026.05.002_bib213","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: A phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nature Medicine"},{"issue":"2","key":"10.1016\/bs.apha.2026.05.002_bib214","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1158\/1078-0432.CCR-09-1303","article-title":"Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy","volume":"16","author":"Sport\u00e8s","year":"2010","journal-title":"Clinical Cancer Research"},{"issue":"7","key":"10.1016\/bs.apha.2026.05.002_bib215","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1084\/jem.20071681","article-title":"Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets","volume":"205","author":"Sport\u00e8s","year":"2008","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/bs.apha.2026.05.002_bib216","doi-asserted-by":"crossref","unstructured":"Stefanidis, E., Semilietof, A., Pujol, J., Seijo, B., Scholten, K., Zoete, V., \u2026 Irving, M. (2024). Combining SiRP\u03b1 decoy\u2013coengineered T cells and antibodies augments macrophage-mediated phagocytosis of tumor cells. The Journal of Clinical Investigation, 134(11), e161660. https:\/\/doi.org\/10.1172\/JCI161660.","DOI":"10.1172\/JCI161660"},{"issue":"8047","key":"10.1016\/bs.apha.2026.05.002_bib217","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"issue":"11","key":"10.1016\/bs.apha.2026.05.002_bib218","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","article-title":"An inducible caspase 9 safety switch for T-cell therapy","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"key":"10.1016\/bs.apha.2026.05.002_bib219","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.2147\/IJN.S297631","article-title":"Nanobody: A small antibody with big implications for tumor therapeutic strategy","volume":"16","author":"Sun","year":"2021","journal-title":"International Journal of Nanomedicine"},{"issue":"18","key":"10.1016\/bs.apha.2026.05.002_bib220","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2408771","article-title":"Enhanced CAR T-cell therapy for lymphoma after previous failure","volume":"392","author":"Svoboda","year":"2025","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1016\/bs.apha.2026.05.002_bib221","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1074-7613(00)80483-5","article-title":"Evidence that a single peptide\u2013MHC complex on a target cell can elicit a cytolytic T cell response","volume":"4","author":"Sykulev","year":"1996","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.002_bib222","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-022-01244-0","article-title":"Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells","volume":"15","author":"Tan","year":"2022","journal-title":"Journal of Hematology & Oncology"},{"issue":"2","key":"10.1016\/bs.apha.2026.05.002_bib223","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/cei.12570","article-title":"T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells","volume":"180","author":"Tan","year":"2015","journal-title":"Clinical and Experimental Immunology"},{"issue":"4","key":"10.1016\/bs.apha.2026.05.002_bib224","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133977","article-title":"TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors","volume":"5","author":"Tang","year":"2020","journal-title":"JCI insight"},{"issue":"11","key":"10.1016\/bs.apha.2026.05.002_bib225","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1007\/s00262-022-03193-6","article-title":"CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy","volume":"71","author":"Tian","year":"2022","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.002_bib226","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/blood.V97.1.63","article-title":"Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft","volume":"97","author":"Tiberghien","year":"2001","journal-title":"Blood"},{"issue":"7952","key":"10.1016\/bs.apha.2026.05.002_bib227","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","article-title":"Co-opting signalling molecules enables logic-gated control of CAR T cells","volume":"615","author":"Tousley","year":"2023","journal-title":"Nature"},{"issue":"7","key":"10.1016\/bs.apha.2026.05.002_bib228","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1093\/jimmun\/vkaf075","article-title":"CD27 costimulation supports metabolic fitness of CD4+ T cells by enhancing de novo nucleotide and protein synthesis","volume":"214","author":"Tran Ngoc Minh","year":"2025","journal-title":"The Journal of Immunology"},{"issue":"7","key":"10.1016\/bs.apha.2026.05.002_bib229","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/CJI.0b013e3180de5d90","article-title":"Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction","volume":"30","author":"Turatti","year":"2007","journal-title":"Journal of Immunotherapy"},{"issue":"6","key":"10.1016\/bs.apha.2026.05.002_bib230","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"The Journal of Clinical Investigation"},{"issue":"7","key":"10.1016\/bs.apha.2026.05.002_bib231","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1158\/0008-5472.CAN-11-3890","article-title":"A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor","volume":"72","author":"Urbanska","year":"2012","journal-title":"Cancer Research"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.002_bib232","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.immuni.2011.04.020","article-title":"The costimulatory molecule CD27 maintains clonally diverse CD8(+) T cell responses of low antigen affinity to protect against viral variants","volume":"35","author":"van Gisbergen","year":"2011","journal-title":"Immunity"},{"issue":"24","key":"10.1016\/bs.apha.2026.05.002_bib233","doi-asserted-by":"crossref","first-page":"10972","DOI":"10.1073\/pnas.1005802107","article-title":"Mixed T cell receptor dimers harbor potentially harmful neoreactivity","volume":"107","author":"van Loenen","year":"2010","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"12","key":"10.1016\/bs.apha.2026.05.002_bib234","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000988","article-title":"CAR-modified cellular therapies in chronic lymphocytic leukemia: Is the uphill road getting less steep?","volume":"7","author":"Vitale","year":"2023","journal-title":"Hemasphere"},{"issue":"10","key":"10.1016\/bs.apha.2026.05.002_bib235","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1073\/pnas.96.10.5486","article-title":"Solution structure and dynamics of a de novo designed three-helix bundle protein","volume":"96","author":"Walsh","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"14","key":"10.1016\/bs.apha.2026.05.002_bib236","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.apha.2026.05.002_bib237","article-title":"Chemokine receptor CCR2b enhanced anti-tumor function of chimeric antigen receptor T cells targeting mesothelin in a non-small-cell lung carcinoma model","volume":"12","author":"Wang","year":"2021","journal-title":"Frontiers in Immunology"},{"issue":"8","key":"10.1016\/bs.apha.2026.05.002_bib238","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jcyt.2021.02.117","article-title":"Combined 4-1BB and ICOS co-stimulation improves anti-tumor efficacy and persistence of dual anti-CD19\/CD20 chimeric antigen receptor T cells","volume":"23","author":"Wang","year":"2021","journal-title":"Cytotherapy"},{"issue":"9","key":"10.1016\/bs.apha.2026.05.002_bib239","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1158\/1078-0432.CCR-23-3841","article-title":"Mesothelin CAR T-cells secreting anti-FAP\/anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma","volume":"30","author":"Wehrli","year":"2024","journal-title":"Clinical Cancer Research: an Official Journal of the American Association for Cancer Research"},{"issue":"ement 1","key":"10.1016\/bs.apha.2026.05.002_bib240","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1182\/blood-2024-201138","article-title":"A phase 1 dose escalation and expansion trial of third-generation CD19-directed CAR T-cells incorporating CD28 and toll-like receptor 2 (TLR2) co-stimulation for relapsed or refractory B-cell non-hodgkin lymphomas (ENABLE-1)","volume":"144","author":"Weinkove","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1016\/bs.apha.2026.05.002_bib241","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11050674","article-title":"CAR T-cells targeting the integrin \u03b1v\u03b26 and co-expressing the chemokine receptor CXCR2 demonstrate enhanced homing and efficacy against several solid malignancies","volume":"11","author":"Whilding","year":"2019","journal-title":"Cancers"},{"issue":"6031","key":"10.1016\/bs.apha.2026.05.002_bib242","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/316832a0","article-title":"Genomic organization of the genes encoding mouse T-cell receptor alpha-chain","volume":"316","author":"Winoto","year":"1985","journal-title":"Nature"},{"issue":"5","key":"10.1016\/bs.apha.2026.05.002_bib243","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1006\/jmbi.2000.4265","article-title":"Stability engineering of antibody single-chain Fv fragments1","volume":"305","author":"W\u00f6rn","year":"2001","journal-title":"Journal of Molecular Biology"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.002_bib244","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/s41419-025-08203-w","article-title":"Preclinical evaluation of TIGIT as a target to enhance efficacy and mitigate T cell exhaustion in multiple myeloma following BCMA-CAR-T therapy","volume":"16","author":"Xia","year":"2025","journal-title":"Cell Death & Disease"},{"issue":"12","key":"10.1016\/bs.apha.2026.05.002_bib245","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1016\/j.immuni.2024.11.005","article-title":"Phase separation of chimeric antigen receptor promotes immunological synapse maturation and persistent cytotoxicity","volume":"57","author":"Xu","year":"2024","journal-title":"Immunity"},{"issue":"5955","key":"10.1016\/bs.apha.2026.05.002_bib246","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/308145a0","article-title":"A human T cell-specific cDNA clone encodes a protein having extensive homology to immunoglobulin chains","volume":"308","author":"Yanagi","year":"1984","journal-title":"Nature"},{"issue":"22","key":"10.1016\/bs.apha.2026.05.002_bib247","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.186268","article-title":"Affinity-tuned mesothelin CAR T cells demonstrate enhanced targeting specificity and reduced off-tumor toxicity","volume":"9","author":"Yang","year":"2024","journal-title":"JCI insight"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.002_bib248","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-10940-8","article-title":"Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment","volume":"7","author":"Yeku","year":"2017","journal-title":"Scientific Reports"},{"issue":"7","key":"10.1016\/bs.apha.2026.05.002_bib249","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ymthe.2022.05.011","article-title":"Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors","volume":"30","author":"Yin","year":"2022","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"issue":"2","key":"10.1016\/bs.apha.2026.05.002_bib250","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006239","article-title":"IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM","volume":"11","author":"Zannikou","year":"2023","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"578","key":"10.1016\/bs.apha.2026.05.002_bib251","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba7308","article-title":"A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity","volume":"13","author":"Zhang","year":"2021","journal-title":"Science Translational Medicine"},{"issue":"10","key":"10.1016\/bs.apha.2026.05.002_bib252","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-14-2085","article-title":"Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma","volume":"21","author":"Zhang","year":"2015","journal-title":"Clinical Cancer Research"},{"issue":"625","key":"10.1016\/bs.apha.2026.05.002_bib253","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg6986","article-title":"A human orthogonal IL-2 and IL-2Rbeta system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia","volume":"13","author":"Zhang","year":"2021","journal-title":"Science Translational Medicine"},{"issue":"4","key":"10.1016\/bs.apha.2026.05.002_bib254","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s11684-017-0543-6","article-title":"CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells","volume":"11","author":"Zhang","year":"2017","journal-title":"Frontiers of Medicine"},{"key":"10.1016\/bs.apha.2026.05.002_bib255","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116439","article-title":"Molecular mechanism of co-stimulatory domains in promoting CAR-T cell anti-tumor efficacy","volume":"227","author":"Zhao","year":"2024","journal-title":"Biochemical Pharmacology"},{"issue":"5","key":"10.1016\/bs.apha.2026.05.002_bib256","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1021\/acscentsci.2c00163","article-title":"Bioorthogonal equipping CAR-T cells with hyaluronidase and checkpoint blocking antibody for enhanced solid tumor immunotherapy","volume":"8","author":"Zhao","year":"2022","journal-title":"ACS Central Science"},{"issue":"17","key":"10.1016\/bs.apha.2026.05.002_bib257","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1073\/pnas.1221609110","article-title":"T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy","volume":"110","author":"Zhong","year":"2013","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"26","key":"10.1016\/bs.apha.2026.05.002_bib258","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1182\/blood-2015-02-628354","article-title":"Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation","volume":"125","author":"Zhou","year":"2015","journal-title":"Blood"}],"container-title":["Advances in Pharmacology","Pharmacology of T-Cell Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358926000311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358926000311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T19:48:51Z","timestamp":1783367331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1054358926000311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9780443470387"],"references-count":258,"URL":"https:\/\/doi.org\/10.1016\/bs.apha.2026.05.002","relation":{},"ISSN":["1054-3589"],"issn-type":[{"value":"1054-3589","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}